Spotlight on Allergy & Immunology

David A. Wohl, MD
Credits: 1.0 CME / MOC / CPE
HIV PrEP: Strategies for Risk Reduction and Improved Adherence
David A. Wohl, MD
Vindico Medical Education

HIV PrEP: Strategies for Risk Reduction and Improved Adherence

Start

Activity Details

Free CME/MOC/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Point(s)
1.0 ACPE Contact Hour(s)
Released: March 15, 2022
Expires: March 14, 2023
60 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for the activity is family medicine physicians, internists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients at high risk for acquiring HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Evaluate complications of untreated HIV as well as the tools for risk assessments and routine screening.
  • Identify patient eligibility and the categories of patients who may benefit from pre-exposure prophylaxis (PrEP).
  • Review the latest clinical evidence regarding current and emerging PrEP therapies, including guidance on medication adherence and risk-reduction counseling.

Activity Description

HIV is a disease that attacks the body’s immune system. Patients with HIV have the capability to transmit the virus to other patients via either sex or sharing of needles or syringes. If HIV is not treated, it can lead to AIDS, which is the most severe phase of HIV infection. Because there is no effective vaccine to prevent HIV transmission, behavioral and biomedical HIV prevention strategies are needed to reduce HIV acquisition. For HIV-uninfected patients, PrEP using antiretroviral medications is an evidence-based method to prevent new infections among those at greatest risk, as data have shown that it is highly effective in individuals who are adherent to taking the PrEP agent. In this CE activity, the faculty for this program will identify the categories of patients who may benefit from PrEP, as well as explore the safety and efficacy of current PrEP therapies, and will utilize the unique ArcheMedX Intelligent Learning Platform.

Statement of Educational Need

Several quality care gaps exist when managing individuals who are at high risk for developing HIV. This insufficient care is attributed to numerous factors, including primary care physicians and other providers who do not perform routine screenings and risk assessments of patients, do not discuss PrEP or any other risk prevention strategies with patients who may exhibit high-risk behaviors, do not actively promote adherence to PrEP or follow up with patients, and who lack competence about current PrEP therapies. As such, an educational initiative discussing these topics is warranted to improve outcomes for patients who are at high risk for acquiring HIV.

Agenda

Introduction - David A. Wohl, MD

Burden of HIV and Tools for Risk Assessment - Latesha Elopre, MD, MSPH

PrEP Therapies and Adherence Strategies - David A. Wohl, MD

Case Presentation & Panel Discussion - All Faculty

Activity Chair

David A. Wohl, MD
Professor of Medicine
Division of Infectious Diseases
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC

Disclosure:
Advisor: Gilead, Merck, ViiV
Consultant: Gilead, Merck, ViiV
Independent Research Contractor: Gilead, Merck, ViiV

Faculty

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, AL

Disclosure: No relevant financial relationships to disclose.

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure:
Independent Research Contractor: Actelion/Janssen, ViiV

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This program is acceptable for 1.0 contact hour of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-22-002-H02-P, effective 03/15/2022. This is a knowledge-based activity, and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 45 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

This enduring material is approved for 1 year from the date of original release, March 15, 2022 to March 14, 2023.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit. Pharmacist learners who submit their NABP and DOB will be reported to the CPE Monitor by Vindico Medical Education directly within 45 days.

Statement of Commercial Support

This activity is supported by an educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC Point(s)
1.0 ACPE Contact Hour(s)
Released: March 15, 2022
Expires: March 14, 2023
60 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for the activity is family medicine physicians, internists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients at high risk for acquiring HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Evaluate complications of untreated HIV as well as the tools for risk assessments and routine screening.
  • Identify patient eligibility and the categories of patients who may benefit from pre-exposure prophylaxis (PrEP).
  • Review the latest clinical evidence regarding current and emerging PrEP therapies, including guidance on medication adherence and risk-reduction counseling.

Activity Description

HIV is a disease that attacks the body’s immune system. Patients with HIV have the capability to transmit the virus to other patients via either sex or sharing of needles or syringes. If HIV is not treated, it can lead to AIDS, which is the most severe phase of HIV infection. Because there is no effective vaccine to prevent HIV transmission, behavioral and biomedical HIV prevention strategies are needed to reduce HIV acquisition. For HIV-uninfected patients, PrEP using antiretroviral medications is an evidence-based method to prevent new infections among those at greatest risk, as data have shown that it is highly effective in individuals who are adherent to taking the PrEP agent. In this CE activity, the faculty for this program will identify the categories of patients who may benefit from PrEP, as well as explore the safety and efficacy of current PrEP therapies, and will utilize the unique ArcheMedX Intelligent Learning Platform.

Statement of Educational Need

Several quality care gaps exist when managing individuals who are at high risk for developing HIV. This insufficient care is attributed to numerous factors, including primary care physicians and other providers who do not perform routine screenings and risk assessments of patients, do not discuss PrEP or any other risk prevention strategies with patients who may exhibit high-risk behaviors, do not actively promote adherence to PrEP or follow up with patients, and who lack competence about current PrEP therapies. As such, an educational initiative discussing these topics is warranted to improve outcomes for patients who are at high risk for acquiring HIV.

Agenda

Introduction - David A. Wohl, MD

Burden of HIV and Tools for Risk Assessment - Latesha Elopre, MD, MSPH

PrEP Therapies and Adherence Strategies - David A. Wohl, MD

Case Presentation & Panel Discussion - All Faculty

Activity Chair

David A. Wohl, MD
Professor of Medicine
Division of Infectious Diseases
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC

Disclosure:
Advisor: Gilead, Merck, ViiV
Consultant: Gilead, Merck, ViiV
Independent Research Contractor: Gilead, Merck, ViiV

Faculty

Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, AL

Disclosure: No relevant financial relationships to disclose.

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure:
Independent Research Contractor: Actelion/Janssen, ViiV

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This program is acceptable for 1.0 contact hour of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-22-002-H02-P, effective 03/15/2022. This is a knowledge-based activity, and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 45 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

This enduring material is approved for 1 year from the date of original release, March 15, 2022 to March 14, 2023.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit. Pharmacist learners who submit their NABP and DOB will be reported to the CPE Monitor by Vindico Medical Education directly within 45 days.

Statement of Commercial Support

This activity is supported by an educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Allergy & Immunology Presentations

1.25 CME
Vindico Medical Education
Expert Perspectives on Current and Emerging Therapies in Chronic Spontaneous Urticaria

Expert Perspectives on Current and Emerging Therapies in Chronic Spontaneous Urticaria

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: September 22, 2022
Expires: September 21, 2023
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, dermatologists, allergy nurse practitioners, allergy physician assistants, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with chronic spontaneous urticaria.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden and impact of chronic spontaneous urticaria (CSU) on health-related quality of life.
  • Examine the role of biomarkers and their implications in CSU management.
  • Evaluate the current and emerging treatments for first, second, and subsequent lines of therapies in patients with CSU—including similarities and differences in the guideline recommendations by major consensus groups.

Activity Description

In this educational activity, expert clinicians will review the burden of CSU on health-related quality of life, the role of biomarkers in the management of CSU, the current treatment guidelines and their similarities and differences, and the clinical data supporting the available and emerging therapies for CSU.

Agenda

Chronic Spontaneous Urticaria: Burden, Clinical Implications of Biomarkers
Kristin Sokol, MD, MPH, MS

CSU Guidelines: Similarities and Differences
Allen P. Kaplan, MD

CSU Management: A Focus on Emerging Therapies
Thomas B. Casale, MD, FACP, FAAAAI, FACAAI

Activity Chair

Allen P. Kaplan, MD
Professor of Medicine
The Medical University of South Carolina
Charleston, SC

Disclosures
Advisor: Abb-RISA, AstraZeneca, Genetech, Novartis, Roche, Sanofi
Consultant: Celldex, Novartis

Faculty

Thomas B. Casale, MD, FACP, FAAAAI, FACAAI
Chief Medical Advisor Food Allergy Research and Education (FARE)
Distinguished Chair, FARE Clinical Network
Professor of Medicine and Pediatrics
Director, Division of Allergy and Immunology Joy McCann Culverhouse Clinical Research Center
University of South Florida
Tampa, FL

Disclosures
Consultant: Genentech, GlaxoSmithKline, Novartis, Sanofi-Regeneron
Speaker Contracted by Ineligible Company: Genentech, GlaxoSmithKline, Sanofi-Regeneron
Independent Research Contractor: Genentech, Sanofi-Regeneron
Data Safety Monitoring Board: Novartis

Kristin Sokol, MD, MPH, MS
Allergist/Immunologist Physician
Schreiber Allergy
Rockville, MD

Disclosures
Speaker Contracted by Ineligible Company: Regeneron/Sanofi

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer Statement

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Notice

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.

Contact Information for Questions About the Activity

CME Questions?
Contact us at cme@vindicoCME.com

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: September 22, 2022
Expires: September 21, 2023
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, dermatologists, allergy nurse practitioners, allergy physician assistants, dermatology nurse practitioners, dermatology physician assistants, and other health care professionals involved in the management of patients with chronic spontaneous urticaria.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden and impact of chronic spontaneous urticaria (CSU) on health-related quality of life.
  • Examine the role of biomarkers and their implications in CSU management.
  • Evaluate the current and emerging treatments for first, second, and subsequent lines of therapies in patients with CSU—including similarities and differences in the guideline recommendations by major consensus groups.

Activity Description

In this educational activity, expert clinicians will review the burden of CSU on health-related quality of life, the role of biomarkers in the management of CSU, the current treatment guidelines and their similarities and differences, and the clinical data supporting the available and emerging therapies for CSU.

Agenda

Chronic Spontaneous Urticaria: Burden, Clinical Implications of Biomarkers
Kristin Sokol, MD, MPH, MS

CSU Guidelines: Similarities and Differences
Allen P. Kaplan, MD

CSU Management: A Focus on Emerging Therapies
Thomas B. Casale, MD, FACP, FAAAAI, FACAAI

Activity Chair

Allen P. Kaplan, MD
Professor of Medicine
The Medical University of South Carolina
Charleston, SC

Disclosures
Advisor: Abb-RISA, AstraZeneca, Genetech, Novartis, Roche, Sanofi
Consultant: Celldex, Novartis

Faculty

Thomas B. Casale, MD, FACP, FAAAAI, FACAAI
Chief Medical Advisor Food Allergy Research and Education (FARE)
Distinguished Chair, FARE Clinical Network
Professor of Medicine and Pediatrics
Director, Division of Allergy and Immunology Joy McCann Culverhouse Clinical Research Center
University of South Florida
Tampa, FL

Disclosures
Consultant: Genentech, GlaxoSmithKline, Novartis, Sanofi-Regeneron
Speaker Contracted by Ineligible Company: Genentech, GlaxoSmithKline, Sanofi-Regeneron
Independent Research Contractor: Genentech, Sanofi-Regeneron
Data Safety Monitoring Board: Novartis

Kristin Sokol, MD, MPH, MS
Allergist/Immunologist Physician
Schreiber Allergy
Rockville, MD

Disclosures
Speaker Contracted by Ineligible Company: Regeneron/Sanofi

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.25 hours credit for completing this program.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

Disclaimer Statement

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Notice

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.

Contact Information for Questions About the Activity

CME Questions?
Contact us at cme@vindicoCME.com

0.25 CME / MOC / IPCE
RMEI Medical Education, LLC
Challenging Cases in Asthma: Optimizing Biologics in Adults

Challenging Cases in Asthma: Optimizing Biologics in Adults

Start

Activity Details

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: August 30, 2022
Expires: August 29, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
  • Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Description

You have a middle-aged patient with severe, steroid-dependent asthma, multiple atopic comorbidities, and who has failed biologic after biologic for asthma. What do you do? Listen to what this expert, interprofessional panel recommends for collaborative care team management of this case and others that learners have submitted for their discussion.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH


Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).

Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
Planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 100% on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: August 30, 2022
Expires: August 29, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
  • Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Description

You have a middle-aged patient with severe, steroid-dependent asthma, multiple atopic comorbidities, and who has failed biologic after biologic for asthma. What do you do? Listen to what this expert, interprofessional panel recommends for collaborative care team management of this case and others that learners have submitted for their discussion.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH


Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).

Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
Planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 100% on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

0.25 CME / MOC / IPCE
RMEI Medical Education, LLC
Challenging Cases in Asthma: Improving Quality of Life

Challenging Cases in Asthma: Improving Quality of Life

Start

Activity Details

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: August 30, 2022
Expires: August 29, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
  • Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Description

This interprofessional expert panel takes on challenging cases in severe and difficult-to-treat asthma, including pediatrics and non-T2 asthma. In their discussions they weigh different treatment strategies; consider atopic comorbidities; illustrate how asthma affects patients’ quality of life; and how they can work as a team to help optimize patient care from a pulmonology, allergy, and nursing perspective.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH


Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).

Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
Planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 100% on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: August 30, 2022
Expires: August 29, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
  • Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Description

This interprofessional expert panel takes on challenging cases in severe and difficult-to-treat asthma, including pediatrics and non-T2 asthma. In their discussions they weigh different treatment strategies; consider atopic comorbidities; illustrate how asthma affects patients’ quality of life; and how they can work as a team to help optimize patient care from a pulmonology, allergy, and nursing perspective.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH


Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).

Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
Planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 100% on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

0.25 CME / MOC / IPCE
RMEI Medical Education, LLC
Reinforcing the Roles of Biologic Therapy and Interprofessional Care in Improving Patient Outcomes in Severe and Difficult-to-Control Asthma

Reinforcing the Roles of Biologic Therapy and Interprofessional Care in Improving Patient Outcomes in Severe and Difficult-to-Control Asthma

Start

Activity Details

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: July 25, 2022
Expires: July 24, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Learning Objectives

  • Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
  • Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
  • Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Description

Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH


Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).

Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
Planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 80% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: July 25, 2022
Expires: July 24, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.

Learning Objectives

  • Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
  • Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
  • Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma

Activity Description

Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.

Faculty

Michael E. Wechsler, MD, MMSc
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO


David M. Lang, MD
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH


Rachel DeCosta, MSN, FNP-C
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.

David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).

Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
Planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 80% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

0.5 CME
National Jewish Health
Reframing the Significance of Airway Hyperresponsiveness in Severe Asthma—Monograph

Reframing the Significance of Airway Hyperresponsiveness in Severe Asthma—Monograph

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: May 27, 2022
Expires: May 27, 2023
30 minutes to complete

Accredited By

National Jewish Health

Target Audience

Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.

Learning Objectives

  • Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma
  • Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management
  • Discuss the implications of AHR for treatment selection in severe asthma
  • Compare the effects of current and emerging biologic therapies on AHR in clinical studies

Activity Description

This activity presents the content from videos 1 and 2 in a text-based monograph as an alternative format. The activity is focused on airway hyperresponsiveness, its clinical significance, and emerging treatments. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.

Statement of Educational Need

Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.

Faculty

Michael E. Wechsler, MD, MMSc
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO


Flavia Cecilia Lega Hoyte, MD
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO


Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board for AstraZeneca. She is also an investigator for Sanofi.
Esther Langmack, MD, has no relevant financial relationships to disclose.
Michael Mohning, MD, has no relevant financial relationships to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi Regeneron. He is also an investigator for AstraZeneca and GlaxoSmithKline.

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

National Jewish Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test with a minimum score of 3 out of 4
  4. Submit the evaluation form.

Certificates will be emailed to the participant.

Statement of Commercial Support

This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Privacy Policy

The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).

We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.

If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices

Contact Information for Questions About the Activity

For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: May 27, 2022
Expires: May 27, 2023
30 minutes to complete

Accredited By

National Jewish Health

Target Audience

Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.

Learning Objectives

  • Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma
  • Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management
  • Discuss the implications of AHR for treatment selection in severe asthma
  • Compare the effects of current and emerging biologic therapies on AHR in clinical studies

Activity Description

This activity presents the content from videos 1 and 2 in a text-based monograph as an alternative format. The activity is focused on airway hyperresponsiveness, its clinical significance, and emerging treatments. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.

Statement of Educational Need

Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.

Faculty

Michael E. Wechsler, MD, MMSc
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO


Flavia Cecilia Lega Hoyte, MD
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO


Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board for AstraZeneca. She is also an investigator for Sanofi.
Esther Langmack, MD, has no relevant financial relationships to disclose.
Michael Mohning, MD, has no relevant financial relationships to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi Regeneron. He is also an investigator for AstraZeneca and GlaxoSmithKline.

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

National Jewish Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test with a minimum score of 3 out of 4
  4. Submit the evaluation form.

Certificates will be emailed to the participant.

Statement of Commercial Support

This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Privacy Policy

The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).

We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.

If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices

Contact Information for Questions About the Activity

For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.

0.25 CME
National Jewish Health
Reframing the Significance of Airway Hyperresponsiveness in Severe Asthma—Clinical Significance of Airway Hyperresponsiveness

Reframing the Significance of Airway Hyperresponsiveness in Severe Asthma—Clinical Significance of Airway Hyperresponsiveness

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 27, 2022
Expires: May 27, 2023
15 minutes to complete

Accredited By

National Jewish Health

Target Audience

Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.

Learning Objectives

  • Discuss the implications of AHR for treatment selection in severe asthma
  • Compare the effects of current and emerging biologic therapies on AHR in clinical studies

Activity Description

This 15-minute video-based activity focuses on airway hyperresponsiveness (AHR) in different asthma phenotypes, clinical challenges in severe asthma, and the impact of current and emerging therapies on AHR. This video also highlights case discussions on non-eosinophilic and eosinophilic asthma. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.

Statement of Educational Need

Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.

Faculty

Michael E. Wechsler, MD, MMSc
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO


Flavia Cecilia Lega Hoyte, MD
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO


Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board for AstraZeneca. She is also an investigator for Sanofi.
Michael Mohning, MD, has no relevant financial relationships to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi Regeneron. He is also an investigator for AstraZeneca and GlaxoSmithKline.

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. View the online activity.
  3. Complete the post-test with a minimum score of 1 out of 2
  4. Submit the evaluation form.

Certificates will be emailed to the participant.

Statement of Commercial Support

This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Privacy Policy

The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).

We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.

If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices

Contact Information for Questions About the Activity

For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 27, 2022
Expires: May 27, 2023
15 minutes to complete

Accredited By

National Jewish Health

Target Audience

Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.

Learning Objectives

  • Discuss the implications of AHR for treatment selection in severe asthma
  • Compare the effects of current and emerging biologic therapies on AHR in clinical studies

Activity Description

This 15-minute video-based activity focuses on airway hyperresponsiveness (AHR) in different asthma phenotypes, clinical challenges in severe asthma, and the impact of current and emerging therapies on AHR. This video also highlights case discussions on non-eosinophilic and eosinophilic asthma. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.

Statement of Educational Need

Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.

Faculty

Michael E. Wechsler, MD, MMSc
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO


Flavia Cecilia Lega Hoyte, MD
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO


Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board for AstraZeneca. She is also an investigator for Sanofi.
Michael Mohning, MD, has no relevant financial relationships to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi Regeneron. He is also an investigator for AstraZeneca and GlaxoSmithKline.

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. View the online activity.
  3. Complete the post-test with a minimum score of 1 out of 2
  4. Submit the evaluation form.

Certificates will be emailed to the participant.

Statement of Commercial Support

This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Privacy Policy

The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).

We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.

If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices

Contact Information for Questions About the Activity

For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.

0.25 CME
National Jewish Health
Reframing the Significance of Airway Hyperresponsiveness in Severe Asthma—Airway Hyperresponsiveness

Reframing the Significance of Airway Hyperresponsiveness in Severe Asthma—Airway Hyperresponsiveness

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 27, 2022
Expires: May 27, 2023
15 minutes to complete

Accredited By

National Jewish Health

Target Audience

Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.

Learning Objectives

  • Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma
  • Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management

Activity Description

This 15-minute video-based activity focuses on defining airway hyperresponsiveness (AHR), pathophysiology of AHR, and AHR testing in clinical practice. The video also includes a detailed animation overviewing the pathophysiology of AHR. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.

Statement of Educational Need

Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.

Faculty

Michael E. Wechsler, MD, MMSc
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO


Flavia Cecilia Lega Hoyte, MD
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO


Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board for AstraZeneca. She is also an investigator for Sanofi.
Michael Mohning, MD, has no relevant financial relationships to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi Regeneron. He is also an investigator for AstraZeneca and GlaxoSmithKline.

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. View the online activity.
  3. Complete the post-test with a minimum score of 1 out of 2
  4. Submit the evaluation form.

Certificates will be emailed to the participant.

Statement of Commercial Support

This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Privacy Policy

The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).

We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.

If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices

Contact Information for Questions About the Activity

For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 27, 2022
Expires: May 27, 2023
15 minutes to complete

Accredited By

National Jewish Health

Target Audience

Pulmonologists, Allergists (MDs and DOs) and Nurse Practitioners and Physician Assistants in these specialties.

Learning Objectives

  • Define AHR and its relationship to epithelial cell function, inflammation, and airway remodeling in asthma
  • Evaluate the role of bronchoprovocation challenge testing in asthma diagnosis and management

Activity Description

This 15-minute video-based activity focuses on defining airway hyperresponsiveness (AHR), pathophysiology of AHR, and AHR testing in clinical practice. The video also includes a detailed animation overviewing the pathophysiology of AHR. The succinct, expert-guided material will provide practical tools for specialists with competing priorities and limited time to integrate into their practice.

Statement of Educational Need

Clinicians are challenged to integrate the volume and complexity of information on the pathophysiology of severe asthma and appropriate interventions for severe asthma into clinical practice. Now is an exciting time for patients with severe asthma, as potential treatments are on the horizon that may impact the cascade of severe asthma inflammation, including T2 and non-T2 or T2-low. However, in order to understand these emerging novel asthma therapies, clinicians need to understand epithelial alarmins and their role in newly described inflammatory processes in severe asthma.

Faculty

Michael E. Wechsler, MD, MMSc
Program Co-Chair
Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO


Flavia Cecilia Lega Hoyte, MD
Program Co-Chair
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health
University of Colorado
Denver, CO


Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.

Faculty, Planner, and Reviewer Disclosures:
Meghan Brenner, MA, has no relevant financial relationships to disclose.
Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant financial relationships to disclose.
Flavia Cecilia Lega Hoyte, MD, declares that she is a speaker for GlaxoSmithKline and AstraZeneca as well as on an advisory board for AstraZeneca. She is also an investigator for Sanofi.
Michael Mohning, MD, has no relevant financial relationships to disclose.
Harold Nelson, MD, declares that he is a consultant for ALK and is on the Data Safety Monitoring Board for AstraZeneca.
Lauren Rieck, MBA, has no relevant financial relationships to disclose.
Michael E. Wechsler, MD, MMSc, declares he is a consultant for AstraZeneca, Amgen, Genzyme, Genentech, GlaxoSmithKline, and Sanofi Regeneron. He is also an investigator for AstraZeneca and GlaxoSmithKline.

Accreditation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

National Jewish Health designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. View the online activity.
  3. Complete the post-test with a minimum score of 1 out of 2
  4. Submit the evaluation form.

Certificates will be emailed to the participant.

Statement of Commercial Support

This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Disclaimer

National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Privacy Policy

The Office of Professional Education of National Jewish Health respects and values your privacy and the confidentiality of the information you choose to share with us. We are committed to protection of this information and will assure your privacy when participating in our Internet Continuing Medical Education (CME).

We do not collect any personal information about a visit unless that information is provided voluntarily. We may collect aggregate information on web pages visited in order to assess and improve the content of our Internet CME programming.

If you decide to register for an Internet CME program, we will collect personal information that you voluntarily share with us. We will only use this information to notify you of future National Jewish Health CME activities.
https://www.nationaljewish.org/education-training/pro-ed/privacy-policy-and-practices

Contact Information for Questions About the Activity

For any questions, please contact the Office of Professional Education at National Jewish Health at proed@njhealth.org.

Jonathan A. Bernstein, MD
0.25 CME / MOC
RMEI Medical Education, LLC
Assessing the Potential Implications of New Data in Chronic Spontaneous Urticaria

Assessing the Potential Implications of New Data in Chronic Spontaneous Urticaria

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: April 19, 2022
Expires: April 18, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
  • Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
  • Assess current safety and efficacy data on emerging therapies for the treatment of CSU

Activity Description

Treatment options for chronic spontaneous urticaria (CSU) are limited, with up to 40% of patients not responding to first-line therapy and a third not responding to second-line treatment. Moreover, many will continue to remain refractory in the third-line setting, highlighting the need for newer therapeutic agents. This Clinical Transfers® activity brings to you the latest data on emerging therapies from this year’s annual meeting of allergists and immunologists in Phoenix, AZ.

Faculty

Jonathan A. Bernstein, MD
Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Jonathan A. Bernstein, MD, has relevant financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Ionis, Genentech, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for this individual has been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: April 19, 2022
Expires: April 18, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
  • Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
  • Assess current safety and efficacy data on emerging therapies for the treatment of CSU

Activity Description

Treatment options for chronic spontaneous urticaria (CSU) are limited, with up to 40% of patients not responding to first-line therapy and a third not responding to second-line treatment. Moreover, many will continue to remain refractory in the third-line setting, highlighting the need for newer therapeutic agents. This Clinical Transfers® activity brings to you the latest data on emerging therapies from this year’s annual meeting of allergists and immunologists in Phoenix, AZ.

Faculty

Jonathan A. Bernstein, MD
Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Jonathan A. Bernstein, MD, has relevant financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Ionis, Genentech, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for this individual has been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

In order to claim MOC points, users must:

  • Provide ABIM ID and month/date of birth and score 75% or higher on the post-test

MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Leonard H. Calabrese, DO
0.25 CME
Vindico Medical Education
Case Conundrums in COVID-19: Primer on the Immune Basis of COVID-19 Progression

Case Conundrums in COVID-19: Primer on the Immune Basis of COVID-19 Progression

Start
Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Describe the role of the innate and adaptive immune response underlying the progression of COVID-19 from early-stage disease to hospitalization to hyperinflammation.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Randy Q. Cron, MD, PhD

Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL

Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Describe the role of the innate and adaptive immune response underlying the progression of COVID-19 from early-stage disease to hospitalization to hyperinflammation.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Randy Q. Cron, MD, PhD

Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL

Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Leonard H. Calabrese, DO
0.25 CME
Vindico Medical Education
Case Conundrums in COVID-19: A Patient Presenting to the ED With Mild COVID-19

Case Conundrums in COVID-19: A Patient Presenting to the ED With Mild COVID-19

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Phyllis C. Tien, MD

Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA

Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: March 30, 2022
Expires: March 29, 2023
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
  • Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.

Activity Description

In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.

Statement of Educational Need

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.

Faculty

Activity Chair
Leonard H. Calabrese, DO

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline

Faculty
Phyllis C. Tien, MD

Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA

Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pages